Clinical Trial Update: ImmunoModulation by the Combination of Ipilimumab and Nivolumab Neoadjuvant to Surgery In Advanced or Recurrent Head and Neck Carcinoma [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating neoadjuvant immunotherapy with ipilimumab and nivolumab prior to surgery in advanced or recurrent head and neck carcinoma has complet…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Cancer

Drugs mentioned

• ipilimumab (ipilimumab)
• nivolumab (nivolumab)

Snippet

Sponsor: The Netherlands Cancer Institute | Conditions: Immunotherapy, Head and Neck Neoplasms | Phase 1, Phase 2 | Status: COMPLETED